Associated Papers
Efavirenz pharmacogenetics in a cohort of Italian patients.
Cusato J et al.
International Journal of Antimicrobial Agents, 2016
Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
Giri AK et al.
Pharmacogenomics, 2014
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL et al.
Clinical Pharmacology and Therapeutics, 2006
Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.
Bravo-Villalta HV et al.
European Journal of Clinical Pharmacology, 2005
Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA et al.
European Journal of Clinical Pharmacology, 2003
Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients.
Takahashi H et al.
Clinical Pharmacology and Therapeutics, 2003
Pharmacogenetics of warfarin elimination and its clinical implications.
Takahashi H et al.
Clinical Pharmacokinetics, 2001
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
Aynacioglu AS et al.
British Journal of Clinical Pharmacology, 1999
Select a paper to view details